drugset / Trial / NCT06800313
Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2028-04
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-101556143 | Unknown | 25 mg | Oral |
| Subject | JNJ-101556143 | Unknown | 50 mg | Oral |